palmitoylethanolamide.com.au
HomeResearchNo 2026

Expression of concern: "Adelmidrol, a Palmitoylethanolamide Analogue, as a New PharmacologicalTreatment for the Management of Inflammatory Bowel Disease" [Mol. Pharmacol. 2016; 90: 549-561] by Cordaro M, Impellizzeri D, Gugliandolo E, et al

No authors listed. Mol Pharmacol. 2026 Apr;108(4):100109.

ReviewOther animals

Design
Review
Subjects
Not stated in the abstract
Dose used in the study
Not stated in the abstract
Duration
Not stated in the abstract
What was measured
Not applicable; this is a publisher's expression of concern notice, not a study report.

What the authors reported

The journal published an expression of concern for the 2016 paper "Adelmidrol, a Palmitoylethanolamide Analogue, as a New Pharmacological Treatment for the Management of Inflammatory Bowel Disease" by Cordaro M, Impellizzeri D, Gugliandolo E et al (PMID 27625036). The PubMed record gives no further detail on the reasons for the concern.

Limits of this study

This is an administrative notice, not a new study. Readers of the original 2016 paper should treat its findings as under review by the journal until the concern is resolved. No conflict or funding information is stated.

Source

PubMed 42062010 · doi:10.1016/j.molpha.2026.100109

Entry checked against the PubMed record; the notice has no abstract on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.